Trembley J H, Wang G, Unger G, Slaton J, Ahmed K
Cellular and Molecular Biochemistry Research Laboratory (151), Veterans Affairs Medical Center, Minneapolis, MN, USA.
Cell Mol Life Sci. 2009 Jun;66(11-12):1858-67. doi: 10.1007/s00018-009-9154-y.
Elevated levels of protein kinase CK2 (formerly casein kinase 2 or II) have long been associated with increased cell growth and proliferation both in normal and cancer cells. The ability of CK2 to also act as a potent suppressor of apoptosis offers an important link to its involvement in cancer since deregulation of both cell proliferation and apoptosis are among the key features of cancer cell biology. Dysregulated CK2 may impact both of these processes in cancer cells. All cancers that have been examined show increased CK2 expression, which may also relate to prognosis. The extensive involvement of CK2 in cancer derives from its impact on diverse molecular pathways controlling cell proliferation and cell death. Downregulation of CK2 by various approaches results in induction of apoptosis in cultured cell and xenograft cancer models suggesting its potential as a therapeutic target.
长期以来,蛋白激酶CK2(以前称为酪蛋白激酶2或II)水平升高与正常细胞和癌细胞的细胞生长及增殖增加有关。CK2作为一种有效的细胞凋亡抑制因子的能力,为其参与癌症提供了重要联系,因为细胞增殖和细胞凋亡的失调都是癌细胞生物学的关键特征。失调的CK2可能会影响癌细胞中的这两个过程。所有已检测的癌症都显示CK2表达增加,这也可能与预后有关。CK2在癌症中的广泛参与源于其对控制细胞增殖和细胞死亡的多种分子途径的影响。通过各种方法下调CK2会导致培养细胞和异种移植癌症模型中细胞凋亡的诱导,表明其作为治疗靶点的潜力。